Introduction
============

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide, with an estimated 950,000 cases and 720,000 deaths per year.[@b1-ott-11-6425] Multiple factors contribute to the pathogenesis of GC, such as smoking, diet, family history and infection of *Helicobacter pylori*.[@b2-ott-11-6425] Despite great improvements in chemo, radio and surgical treatments, the 5-year overall survival rate remains poor.[@b3-ott-11-6425] Approximately 60% of GC patients are in an advanced stage and metastasis at initial diagnosis, resulting in a poor prognosis.[@b4-ott-11-6425] Moreover, several genes are identified in association with the development and progression of GC, but the mechanism remains unclear.[@b5-ott-11-6425]

In recent years, with the development of high-throughput gene-detecting technology, many studies adopted microar-rays to identify genes associated with GC progression.[@b6-ott-11-6425],[@b7-ott-11-6425] However, most studies ignored the high interconnection between genes are probably correlated in function although genes have similar expression patterns and only focused on the screening of differentially expressed genes.[@b8-ott-11-6425] Identification of GC prognostic biomarkers might be clinically important. A systems biology algorithm of weighted gene co-expression network analysis (WGCNA) has been used to evaluate the association between genes sets and clinical traits by constructing a scale-free gene co-expression network.[@b9-ott-11-6425]--[@b11-ott-11-6425] Thus, we applied the WGCNA algorithm to identify network-centric genes associated with the progression and prognosis of GC.

Materials and methods
=====================

Data collection
---------------

Microarray datasets were downloaded from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) and performed on Affymetrix Human Genome U133 Plus 2.0 Array platform (GPL570). Data-set GSE34942[@b12-ott-11-6425] was used as a training set to construct co-expression networks and identify hub genes in this study. This dataset included 56 samples of primary GC with different Lauren type and TNM stages. Two samples with no clinical data (GSM858086 and GSM858122) were removed from the subsequent analyses. Another dataset of GSE13911[@b13-ott-11-6425] was used as a testing set to verify our results. This dataset included 31 adjacent normal tissues and 38 GC tissues. Meanwhile, RNA-sequencing data of 367 GC samples and relevant clinical data were downloaded from database of The Cancer Genome Atlas (TCGA) (<http://genome-cancer.ucsc.edu/>) to further validate our results. The detailed clinical data of training set and testing set are shown in [Table S1](#SD3-ott-11-6425){ref-type="supplementary-material"}.

Data preprocessing
------------------

Raw microarray data were calculated by robust multiarray average (RMA) background correction and log~2~ transformed and normalized by quantile normalization. Then, median-polish probesets was used in the "affy" R package to summarize. At last, we annotated probes by the Affymetrix annotation files. Microarray quality was evaluated by sample clustering association with Pearson's correlation matrices between different samples. Then, we chose a height of 0.2 as the cutoff criteria to identify potential microarray outliers. We filtered probes by their variances, and probes with variances ranked in top 10,000 were used for WGCNA.[@b14-ott-11-6425]

Co-expression network construction
----------------------------------

WGCNA package in R was used to construct co-expression network for the filtered genes in GSE34942.[@b8-ott-11-6425],[@b15-ott-11-6425] First, Pearson's correlation matrices were calculated between pairwise genes. Then, a weighted adjacency matrix was performed by a power function a~m~=\|c~mn~\|^®^ (c~mn~=Pearson's correlation between gene m and gene n; a~mn~=adjacency between gene m and gene n). The soft threshold power *β* could emphasize penalize weak correlations and strong correlations between genes.[@b16-ott-11-6425],[@b17-ott-11-6425] Next, the adjacencies were transformed into topological overlap matrix (TOM).[@b18-ott-11-6425] Then, in order to classify genes with similar expression profiles into modules, average linkage hierarchical clustering was performed by the TOM-based dissimilarity with a minimum module size of 30 for the genes dendrogram.[@b11-ott-11-6425] At last, the dissimilarity of module eigengenes (MES) was calculated for module dendrogram and some modules were merged.

Identification of clinical significant modules and functional annotation
------------------------------------------------------------------------

Two approaches were applied to identify association of modules with clinical traits. Gene significance (GS) was defined as correlation between the genes and clinical data, and the average GS for all the genes in a module was defined as module significance (MS). Additionally, the major component analysis for each gene module was defined as MES and the expression patterns of genes could be generalized into a single characteristic expression profile within a given module. After calculating the association with GS and MES, the module with the mostly absolute MS among all the selected modules was defined as the one related to clinical trait. To further analyze the potential function of module genes, DAVID (<http://david.abcc.ncifcrf.gov/>) database was used along with gene GO functional enrichment analysis. False discovery rate (FDR) \<0.01 was set as the cutoff criteria.

Identification of hub genes
---------------------------

Hub genes comprise highly interconnected nodes within a module and have been shown to be functionally significant.[@b19-ott-11-6425] In this study, we chose a significant module, and hub genes were considered with highly module membership (MM) measured by Pearson's correlation (correlation. weighted \>0.8)[@b20-ott-11-6425],[@b21-ott-11-6425] Also, hub genes in the module showed the highest correlation with the clinical trait. Furthermore, the significant module was constructed using the protein--protein interaction (PPI) network with a combined score of ≥0.4, which was regarded as a positive interaction between genes based on the STRING database (<http://www.string-db.org/>).[@b22-ott-11-6425] A connectivity degree of ≥10 was also defined as a hub gene. We regarded the common hub genes in the co-expression network and PPI network as "real" hub genes for further analysis.

Hub gene validation
-------------------

Gene Expression Profiling Interactive Analysis (GEPIA) database (<http://gepia.cancer-pku.cn>) was used to validate the correlation between the expression levels of hub genes and the stages. We also used the testing set of GSE13911 and Oncomine database (<http://www.oncomine.org>) to check the expression values of the hub gene in normal gastric tissues and GC tissues. Then, the Human Protein Atlas (<http://www.proteinatlas.org>) was used for immunohistochemistry validation. In addition, Kaplan--Meier plotter (<http://www.kmplot>. com) was used to estimate the prognosis including 1,065 GC patients. The GC patients were divided into two groups according to the expression of a particular gene (high vs low expression). The testing set of RNA-sequencing data including 367 GC samples was also applied for survival analyses. The survival curve was generated by log-rank estimator, and the association between hub gene and survival was calculated using the Cox proportional hazards regression model. Difference with statistical significance was defined as *P*\<0.05.

Gene set enrichment analysis (GSEA)
-----------------------------------

In all, 367 GC samples from RNA-sequencing data were divided into two groups according to the median values of the expression of hub genes (high vs low expression). GSEA was performed using the two groups to identify potential function of the hub gene[@b23-ott-11-6425] and chose the annotated gene sets of c2.cp.kegg.v5.2.symbols.gmt as the reference gene sets. Differences at nominal *P*\<0.05, FDR \<0.05 and enrichment score (ES) \>0.6 were defined as the cutoff criteria.

Results
=======

Data preprocessing
------------------

After data preprocessing, the 54 GC samples in the training set GSE34942 were obtained. According to the outlier detection, no samples were removed in the training set ([Figure S1](#SD1-ott-11-6425){ref-type="supplementary-material"}). Under the threshold of variance, we selected probes with the variances ranked in top 10,000 for subsequent analysis.

Weighted co-expression network construction and identification of key modules
-----------------------------------------------------------------------------

In all, 54 GC samples with complete clinical data were used for co-expression analysis. We used WGCNA package on R to put probes with variances ranked in top 10,000 into modules by average linkage clustering ([Figure 1A](#f1-ott-11-6425){ref-type="fig"}). In this study, we selected the power of *β*=9 (scale-free *R*^2^=0.89) as the soft thresholding to ensure a scale-free network ([Figure 1B and C](#f1-ott-11-6425){ref-type="fig"}). A total of 11 modules were identified ([Figure 2A](#f2-ott-11-6425){ref-type="fig"}). The relevance between module and clinical traits was tested using two methods. First, we found the highest MES between the purple module and TNM stage ([Figure 2B](#f2-ott-11-6425){ref-type="fig"}). Afterward, the purple module also had the highest MS in relation to the TNM stage ([Figure 2C](#f2-ott-11-6425){ref-type="fig"}). Thus, we identified that the purple module was the most relevant to the TNM stage in the training set.

To get a primary understanding of the biological relevance of purple module, 185 genes of purple module were enriched by using DAVID database for GO functional enrichment analysis. Top 20 biological processes enriched in GO terms ([Figure 2D](#f2-ott-11-6425){ref-type="fig"}). The genes in the purple module mainly enriched in "vasculature development", "biological adhesion", "extracellular structure organization", "multicellular organismal macromolecule metabolic process", "multicellular organism metabolic process" and "skeletal system development".

Identification of hub genes for TNM stage in the purple module
--------------------------------------------------------------

Highly interconnected hub genes within a module have been shown to have important roles in the biological processes.[@b24-ott-11-6425] Therefore, 12 genes associated with the high connectivity in the purple module (correlate.weighted \>0.8) were identified as hub genes ([Table 1](#t1-ott-11-6425){ref-type="table"}). Based on the STRING database, a PPI network for all genes in the purple module was constructed using Cytoscape ([Figure S2](#SD2-ott-11-6425){ref-type="supplementary-material"}). We identified genes with a connectivity degree of ≥10 as hub genes in the PPI network. Finally, CDH11, MMP2, LUM, FNB1, VCAN and COL8A1 in both co-expression network and PPI network were defined as "real" hub genes ([Table 1](#t1-ott-11-6425){ref-type="table"}).

Hub gene validation
-------------------

In the training set, GSE34942 was used for linear regression analyses to validate hub genes. CDH11 was found to have a higher correlation with the TNM stage (*R*^2^=0.852) and was strongly correlated with biological adhesion based on GO functional enrichment analysis. Furthermore, expression of CDH11 in the diffuse-type GC was higher than that in the intestinal-type GC ([Figure 3C](#f3-ott-11-6425){ref-type="fig"}). Thus, CDH11 was taken as the candidate gene for further validation. Based on the GEPIA dataset, we validated that CDH11 expression had a strong positive correlation with GC stages (*P*\<0.0001; [Figure 3A](#f3-ott-11-6425){ref-type="fig"}). In the testing set GSE13911 and Oncomine dataset, CDH11 was more highly expressed in GC tissues than in normal tissues (*P*\<0.0001; [Figure 3B and D](#f3-ott-11-6425){ref-type="fig"}). Then, immunohistochemistry staining validated from the Human Protein Atlas database revealed that CDH11 protein was significantly higher in GC tissues compared with normal gastric tissues ([Figure 3E](#f3-ott-11-6425){ref-type="fig"}). As the tumor progression always affected the tumor prognosis, we performed a further validation of CDH11. Based on the testing set of RNA-sequencing data, a higher expression of CDH11 in GC patients showed a significantly poorer overall survival time (HR: 1.448, 95% CI: 1.009--2.007, *P*=0.042; [Figure 3F](#f3-ott-11-6425){ref-type="fig"}). More convincingly, Cox proportional hazards regression model performed using the RNA-sequencing data demonstrated that CDH11 expression was an independent predictor for overall survival time of GC (HR=1.482, 95% CI: 1.015--2.164, *P*=0.045; [Table 2](#t2-ott-11-6425){ref-type="table"}). In addition, survival analysis was conducted using the Kaplan--Meier plotter online tool, and a higher expression of CDH11 in GC patients also showed a poorer prognosis ([Figure 3G](#f3-ott-11-6425){ref-type="fig"}).

Gene set enrichment analysis
----------------------------

To characterize the potential mechanisms of CDH11 in association with GC, GSEA was applied to obtain biological process enriched in CDH11 with highly expressed samples. Then, 20 functional gene sets were enriched, and six representative pathways were "regulation of actin cytoskeleton", "focal adhesion", "pathways in cancer", "TGF-β signaling pathway", "ECM receptor interaction" and "MAPK signaling pathway" ([Figure 4](#f4-ott-11-6425){ref-type="fig"} and [Table S2](#SD4-ott-11-6425){ref-type="supplementary-material"}).

Discussion
==========

CDH11 (also known as OB cadherin) is a member of the cadherin superfamily, a group of transmembrane proteins that principally mediated homophilic cell-to-cell adhesion.[@b25-ott-11-6425],[@b26-ott-11-6425] Mature cadherin proteins are composed of a large *N*-terminal extracellular domain, a single membrane-spanning domain and a small highly conserved C-terminal cytoplasmic domain.[@b27-ott-11-6425] In addition, Kalluri and Weinberg[@b28-ott-11-6425] reported that cell adhesion molecules were associated with epithelial to mesenchymal transition (EMT), which suggests that CDH11 plays a critical role in cancer progression. Furthermore, CDH11 expression was linked with many pathologic processes, such as inflammation and fibrosis, which played an important role in the progression from chronic inflammation to cancer.[@b23-ott-11-6425],[@b29-ott-11-6425] In addition, CDH11 has been implicated in prostate, breast and colorectal cancer metastases.[@b30-ott-11-6425]--[@b32-ott-11-6425]

In this study, we identified and validated gene co-expression modules related to the progression of GC by WGCNA. In all, 12 hub genes were identified that were significantly correlated with the TNM stage of GC patients. The GO functional annotation of module genes that were enriched in system development, biological adhesion, extracellular structure organization and metabolic process. CDH11 was mostly highly correlated with TNM stage and strongly correlated with biological adhesion, and expression of CDH11 in diffuse-type GC was higher than that in intestinal-type GC. Qiu et al[@b33-ott-11-6425] found that patients with diffuse-type GC progress faster and have 5-year survival rate poorer than those with intestinal-type GC. Thus, we speculated that CDH11 might affect the TNM stage and prognosis of GC patients.

However, very few studies have identified the role of CDH11 in GC.[@b34-ott-11-6425] In our study, CDH11 was positively correlated with GC stages based on the GEPIA dataset. Additionally, in the testing set GSE13911 and Oncomine dataset, we also found a significantly overexpression of CDH11 in GC tissues. We also used the Human Protein Atlas database to find that the CDH11 protein was significantly higher in GC tissues. Several investigators demonstrated that CD11 was a mesenchymal cadherin in association with more undifferentiated and aggressive cancers, such as pancreatic cancer, prostate cancer, breast cancer and colorectal cancer.[@b27-ott-11-6425]--[@b30-ott-11-6425] As a result, the overexpression of CDH11 might be related to malignant nature of GC. As we know, TNM staging system has been used for prognostic prediction. Thus, genes related to TNM stage were supposed to be associated with the prognosis. Moreover, the prognostic value of CDH11 had been identified in prostate cancer, breast cancer, colorectal cancer, glioblastoma and osteosarcoma.[@b28-ott-11-6425]--[@b30-ott-11-6425],[@b35-ott-11-6425],[@b36-ott-11-6425] However, no evidence revealing the role of overexpression of CDH11 related to the prognosis of GC. In our study, we performed survival analysis to validate the role of CDH11 in GC prognosis, and the highly expressed CDH11 was related to a shorter overall survival time. Furthermore, Cox regression analysis was performed on the RNA-sequencing data and demonstrated that CDH11 expression was an independent predictor for the prognosis of GC. Thus, the expression of CDH11 might be positively correlated with the progression and prognosis in GC.

As for the functional annotation, CDH11 was strongly correlated with biological adhesion, and we conducted GSEA analysis to reveal that CDH11 with highly expressed samples was enriched in regulation of focal adhesion, which was closely related to cancer development.[@b37-ott-11-6425],[@b38-ott-11-6425] Focal adhesion consists of cell-extracellular components, actin cytoskeleton and integrin.[@b39-ott-11-6425] It was reported that focal adhesion was significantly associated with multiple biological processes, such as cell proliferation, cell differentiation and cell survival.[@b40-ott-11-6425] Tomkiewicz et al[@b41-ott-11-6425] reported a novel cell-migratory program that the AhR through the activation of Src activates FAK and promotes integrin clustering and the activation of the AhR increases the interaction of FAK with the metastatic marker, HEF1/NEDD9/CAS-L and the expression of several integrins. McAndrews et al[@b42-ott-11-6425] elucidated that CDH11 promoted breast, ovarian and prostate cancer cell growth, survival and invasion by targeting cell adhesion molecules and blockade of CDH11 on stromal cells inhibited adhesion. According to our results, we could speculate that the overexpressed CDH11 might lead to cancer cell growth, migration and invasion of GC by regulating focal adhesion pathway. In addition, the expression of CDH11 may be positively associated with the degree of malignancy and prognosis of GC.

Some limitations of our study should be mentioned. First, this was a retrospective design study rather than a prospective cohort study. In addition, a large number of samples are required to validate our finding.

Conclusion
==========

Our study adopted systems biology-based WGCNA method to identify and validate network hub genes in association with the GC clinical traits. Finally, CDH11 was identified and validated in association with progression and prognosis in GC, probably, by regulating biological adhesion and focal adhesion-related pathways.

Supplementary materials
=======================

###### 

Clustering of samples to detect outliers.

###### 

PPI network of genes in the purple module.

**Notes:** The color intensity of node was correlation. weighted (positive in red and negative in green). The nodes with bold circle are hub genes identified by WGCNA. The edge width was node to the score of PPI based on the STRING database.

**Abbreviations:** PPI, protein--protein interaction; WGCNA, weighted gene co-expression network analysis.

###### 

Clinical information of GC patients in training set and testing set

  Characteristics   Training set (GSE34942)   Testing set (TCGA)
  ----------------- ------------------------- --------------------
                                              
  Age (years)                                 
   ≥65              --                        176
   \<65             --                        191
  Sex                                         
   Female           20                        133
   Male             34                        234
  Grade                                       
   G1               --                        8
   G2               --                        128
   G3               --                        231
  Lauren type                                 
   Diffuse          11                        --
   Intestinal       39                        --
   Mixed            4                         --
  M                                           
   M0               --                        349
   M1               --                        18
  N                                           
   N0                                         117
   N1               --                        102
   N2               --                        79
   N3               --                        69
  T                                           
   T1               --                        20
   T2               --                        77
   T3               --                        172
   T4               --                        98
  TNM stage                                   
   I                11                        47
   II               11                        123
   III              19                        167
   IV               13                        30

**Note:** "--"= no data available.

**Abbreviations:** GC, gastric cancer; TCGA, The Cancer Genome Atlas.

###### 

Gene set enriched in GC with CDH11 high expression

  Name                                   ES           NES         NOM *p*-val   FDR *q*-val
  -------------------------------------- ------------ ----------- ------------- -------------
                                                                                
  Regulation of actin cytoskeleton       0.60052013   2.5375714   0             0
  Focal adhesion                         0.7055633    2.4970698   0             0
  Pathways in cancer                     0.668618     2.478331    0             0
  TGF-β signaling pathway                0.6422774    2.3762345   0             3.39E--04
  ECM receptor interaction               0.6796672    2.350076    0             5.10E--04
  MAPK signaling pathway                 0.66236047   2.3040917   0             0.001043
  Melanoma                               0.6947667    2.2726984   0             0.001228
  Hedgehog signaling pathway             0.61025055   2.2306397   0             0.001314
  Renal cell carcinoma                   0.6499811    2.240766    0             0.00134
  Basal cell carcinoma                   0.7672358    2.2342017   0             0.001341
  Gap junction                           0.6081262    2.215631    0             0.001385
  Vascular smooth muscle contraction     0.60214245   2.1982234   0             0.001392
  Wnt signaling pathway                  0.6044263    2.2845821   0             0.001403
  Melanogenesis                          0.6075048    2.230943    0             0.001408
  Axon guidance                          0.6870838    2.2417881   0             0.001462
  HCM                                    0.6112746    2.1997008   0             0.001474
  Leukocyte transendothelial migration   0.6143261    2.2572083   0             0.001572
  Dilated cardiomyopathy                 0.6986659    2.2481806   0             0.001608
  Fc_gamma_r mediated phagocytosis       0.6079453    2.1730387   0             0.001757
  Arrhythmogenic right ventricular       0.6713229    2.179226    0             0.001786

**Abbreviations:** GC, gastric cancer; ES, enrichment score; NES, normalized enrichment score; NOM *p*-val, nominal *p*-value; FDR *q*-val, false discovery rate *q*-value; ECM, extracellular matrix; HCM, hypertrophic cardiomyopathy.
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![Samples clustering dendrogram and clinical traits indicator and determination of soft-thresholding power in WGCNA.\
**Notes:** (**A**) The clustering was based on the expression data of probes with variances ranked in top 10,000 in tumor samples. The red color represents male. The color intensity was proportional to older age as well as Lauren type and higher TNM stage. (**B**) Analysis of the scale-free fit index for various soft-thresholding powers (*β*). (**C**) Analysis of the mean connectivity for various soft-thresholding powers.\
**Abbreviation:** WGCNA, weighted gene co-expression network analysis.](ott-11-6425Fig1){#f1-ott-11-6425}

![Modules associated with the clinical traits of GC.\
**Notes:** (**A**) Clustering dendrogram of genes based on a dissimilarity measure (1-TOM). (**B**) Heatmap of the association with MES and clinical traits of GC. (**C**) Average GS and errors in the modules associated with TNM stage of GC. (**D**) GO functional annotation genes in the purple module. The y-axis shows the GO terms, and x-axis shows the −log~10~(FDR q-value) of each term.\
**Abbreviations:** GC, gastric cancer; TOM, topological overlap matrix; MES, module eigengenes; GS, gene significance; FDR, false discovery rate.](ott-11-6425Fig2){#f2-ott-11-6425}

![Validation of CDH11.\
**Notes:** (**A**) CDH11 expression was correlated with stages of GC (based on the dataset in GEPIA). (**B**) CDH11 expression was associated with the progression of GC (GSE13911). (**C**) CDH11 expression was significantly higher in diffuse-type GC compared with that in intestinal-type GC (GSE34942). (**D**) CDH11 expression was significantly higher in GC tissues compared with that in normal tissues based on the Oncomine database. (**E**) The Human Protein Atlas database indicated that CD11 protein was strongly higher in GC tissues compared with that in normal tissues. (**F**) Survival analysis of the association of CDH11 expression with overall survival time in GC (based on RNA-sequencing data). (**G**) Prognostic value of CDH11 was obtained using the Kaplan--Meier Plotter online tool.\
**Abbreviations:** GC, gastric cancer; GEPIA, Gene Expression Profiling Interactive Analysis.](ott-11-6425Fig3){#f3-ott-11-6425}

![GSEA.\
**Note:** The six most common functional gene sets enriched in GC samples with highly expressed CDH11 are listed.\
**Abbreviations:** GSEA, gene set enrichment analysis; GC, gastric cancer; ES, enrichment score.](ott-11-6425Fig4){#f4-ott-11-6425}

###### 

Hub genes in the module related to TNM stage

  Gene     Probe          Co-expression analysis   Hub gene in PPI   
  -------- -------------- ------------------------ ----------------- -----
                                                                     
  CDH11    207173_x\_at   1.16E--07                0.852046733       Yes
  MMP2     201069_at      2.06E--07                0.841262999       Yes
  LUM      229554_at      6.33E--07                0.834838902       Yes
  FBN1     235318_at      8.27E--07                0.826947407       Yes
  VCAN     204619_s\_at   2.10E--06                0.811054746       Yes
  COL8A1   226237_at      6.03939E--06             0.80063548        Yes
  GLT8D2   227070_at      4.81E--07                0.839699191       No
  PDPN     221898_at      7.19E--07                0.829936379       No
  ANTXR1   224694_at      1.55E--06                0.820542674       No
  TRIL     205150_s\_at   1.86E--06                0.817861853       No
  MRC2     37408_at       3.58E--06                0.808042862       No
  PLXDC2   226865_at      4.56E--06                0.802553004       No

**Abbreviation:** PPI, protein--protein interaction.

###### 

Prognostic factors for overall survival of GC patients estimated by univariate and multivariate Cox regression analyses

  Characteristics    Univariate analysis   Multivariate analysis                                   
  ------------------ --------------------- ----------------------- ------- ------- --------------- -------
                                                                                                   
  Age (years)                                                                                      
   ≤65               1                     --                      --      1       --              --
   \>65              1.641                 1.138--2.364            0.008   2.141   1.147--3.166    0.013
  Sex                                                                                              
   Male              1                     --                      --      1       --              --
   Female            0.651                 0.437--0.972            0.036   0.701   0.463--1.059    0.092
  Grade                                                                                            
   G1                1                     --                      --      1       --              --
   G2                1.945                 0.267--14.163           0.511   2.491   0.329--18.826   0.377
   G3                2.572                 0.357--18.518           0.348   5.574   0.482--26.478   0.213
  M stage                                                                                          
   M0                1                     --                      --      1       --              --
   M1                1.996                 0.971--4.104            0.061   1.398   0.523--3.739    0.504
  N stage                                                                                          
   N0                1                     --                      --      1       --              --
   N1                1.341                 0.808--2.226            0.257   1.371   0.629--2.988    0.427
   N2                1.705                 1.012--2.872            0.045   1.557   0.619--3.918    0.347
   N3                2.166                 1.289--3.639            0.004   1.781   0.682--4.654    0.239
  T stage                                                                                          
   T1                1                     --                      --      1       --              --
   T2                2.784                 0.655--11.831           0.165   2.328   0.506--10.714   0.278
   T3                3.816                 0.932--15.361           0.063   3.515   0.654--18.899   0.143
   T4                4.462                 1.116--19.309           0.035   3.681   0.664--20.391   0.136
  TNM stage                                                                                        
   I                 1                     --                      --      1       --              --
   II                1.072                 0.539--2.132            0.843   0.513   0.184--1.429    0.202
   III               1.937                 1.041--3.607            0.037   1.57    1.012--2.437    0.043
   IV                3.050                 1.466--6.353            0.003   2.372   1.125--5.005    0.023
  CDH11 expression                                                                                 
   Low               1                     --                      --      1       --              --
   High              1.485                 1.038--2.215            0.031   1.482   1.015--2.164    0.045

**Abbreviation:** GC, gastric cancer.
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